Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia

被引：1
|
作者：
Maeda, Takuya [1 ]
Hiura, Azusa [1 ]
Uehara, Jiro [1 ]
Toyoshima, Rino [1 ]
Nakagawa, Tomoe [1 ]
Yoshino, Koji [1 ]
机构：
[1] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Dermatol Oncol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF DERMATOLOGY | 2021年 / 31卷 / 05期
关键词：
JAPANESE PATIENTS; SAFETY;
D O I：
10.1684/ejd.2021.4139
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：662 / 664
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of nivolumab in metastatic melanoma: real-world practice
    Solène Bocquet-Tremoureux
    Emeric Scharbarg
    Jean-Michel Nguyen
    Emilie Varey
    Gaëlle Quereux
    Melanie Saint-Jean
    Lucie Peuvrel
    Amir Khammari
    Brigitte Dreno
    European Journal of Dermatology, 2019, 29 : 315 - 321
  • [42] Real-world evidence in melanoma: A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
    Eigentler, T.
    Gutzmer, R.
    Mohr, P.
    Kaatz, M.
    Pfohler, C.
    Terheyden, P.
    Ulrich, J.
    Utikal, J.
    Zimmer, L.
    Schadendorf, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 159 - 159
  • [43] Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
    Serra-Bellver, Patricio
    Versluis, Judith M.
    Oberoi, Honey K.
    Zhou, Cong
    Slattery, Timothy D.
    Khan, Yasir
    Patrinely, James R.
    da Silva, Ines Pires
    Martinez-Vila, C.
    Cook, Natalie
    Graham, Donna M.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Arance, Ana M.
    Johnson, Douglas B.
    Long, Georgina, V
    Pickering, Lisa
    Larkin, James M. G.
    Blank, Christian U.
    Lorigan, Paul
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 121 - 132
  • [44] Trial in progress: clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401
    Dummer, R.
    Gutzmer, R.
    Corrie, P.
    Millward, M.
    Murzhenko, A.
    Maio, M.
    MELANOMA RESEARCH, 2016, 26 : E43 - E43
  • [45] TEMPORAL TRENDS IN ADVERSE EVENT COSTS WITH NIVOLUMAB plus RELATLIMAB COMBINATION THERAPY OR NIVOLUMAB MONOTHERAPY FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
    Garcia-Horton, V
    Zhou, Z. Y.
    Moshyk, A.
    Rosenblatt, L. C.
    Patel, D.
    Xin, Y.
    Wang, Q.
    Christensen, D.
    Palaia, J.
    VALUE IN HEALTH, 2023, 26 (06) : S108 - S108
  • [46] The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis
    Zhu, Yuqing
    Cheng, Hui
    Zhong, Minhong
    Hu, Yijie
    Li, Qiushuang
    Gao, Xiangfu
    Liu, Shan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (07) : 1679 - +
  • [47] Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge
    Kibata, K.
    Yokoi, T.
    Yoshioka, H.
    Kurata, T.
    Nomura, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
    Rangwala, Hussain Sohail
    Fatima, Hareer
    Ali, Mirha
    Sunder, Sailesh
    Devi, Sonia
    Rangwala, Burhanuddin Sohail
    Abbas, Syed Raza
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2024, 36 (01)
  • [49] Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
    Zimmer, Lisa
    Livingstone, Elisabeth
    Hassel, Jessica C.
    Fluck, Michael
    Eigentler, Thomas
    Loquai, Carmen
    Haferkamp, Sebastian
    Gutzmer, Ralf
    Meier, Friedegund
    Mohr, Peter
    Hauschild, Axel
    Schilling, Bastian
    Menzer, Christian
    Kieker, Felix
    Dippel, Edgar
    Roesch, Alexander
    Simon, Jan-Christoph
    Conrad, Beate
    Koerner, Silvia
    Windemuth-Kieselbach, Christine
    Schwarz, Leonora
    Garbe, Claus
    Becker, Juergen C.
    Schadendorf, Dirk
    LANCET, 2020, 395 (10236): : 1558 - 1568
  • [50] Tumor lysis syndrome associated with nivolumab plus ipilimumab combination therapy in a melanoma patient
    Magara, Azusa
    Kato, Hiroshi
    Oda, Takao
    Nakamura, Motoki
    Komatsu, Hirokazu
    Morita, Akimichi
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : E411 - E412
12345